New drug indication approval - April 2022
|
Product Name
|
MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ML
|
|
Active Ingredient
|
Gemtuzumab ozogamicin
|
|
Product Registrant
|
PFIZER PRIVATE LIMITED
|
|
Date of Approval
|
21/04/2022
|
|
Indications:
MYLOTARG is indicated for the treatment of newly-diagnosed, de novo CD33- positive acute myeloid leukemia in adults and pediatric patients 1 month and older, except acute promyelocytic leukemia (APL).
|
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals